Incyte Corporation (INCY)
NASDAQ: INCY · Real-Time Price · USD
96.91
+1.64 (1.72%)
At close: May 1, 2026, 4:00 PM EDT
97.64
+0.73 (0.76%)
After-hours: May 1, 2026, 7:49 PM EDT
Incyte Employees
Incyte had 2,844 employees as of December 31, 2025. The number of employees increased by 227 or 8.67% compared to the previous year.
Employees
2,844
Change (1Y)
227
Growth (1Y)
8.67%
Revenue / Employee
$1,885,028
Profits / Employee
$503,438
Market Cap
19.36B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 2,844 | 227 | 8.67% |
| Dec 31, 2024 | 2,617 | 93 | 3.68% |
| Dec 31, 2023 | 2,524 | 200 | 8.61% |
| Dec 31, 2022 | 2,324 | 230 | 10.98% |
| Dec 31, 2021 | 2,094 | 321 | 18.10% |
| Dec 31, 2020 | 1,773 | 317 | 21.77% |
| Dec 31, 2019 | 1,456 | 89 | 6.51% |
| Dec 31, 2018 | 1,367 | 159 | 13.16% |
| Dec 31, 2017 | 1,208 | 228 | 23.27% |
| Dec 31, 2016 | 980 | 288 | 41.62% |
| Dec 31, 2015 | 692 | 104 | 17.69% |
| Dec 31, 2014 | 588 | 107 | 22.25% |
| Dec 31, 2013 | 481 | 68 | 16.46% |
| Dec 31, 2012 | 413 | 45 | 12.23% |
| Dec 31, 2011 | 368 | 121 | 48.99% |
| Dec 31, 2010 | 247 | 26 | 11.76% |
| Dec 31, 2009 | 221 | 9 | 4.25% |
| Dec 31, 2008 | 212 | 16 | 8.16% |
| Dec 31, 2007 | 196 | 10 | 5.38% |
| Dec 31, 2006 | 186 | 9 | 5.08% |
| Dec 31, 2005 | 177 | -9 | -4.84% |
| Dec 31, 2004 | 186 | -268 | -59.03% |
| Dec 31, 2003 | 454 | -37 | -7.54% |
| Dec 31, 2002 | 491 | -94 | -16.07% |
| Dec 31, 2001 | 585 | -737 | -55.75% |
| Dec 31, 2000 | 1,322 | 214 | 19.31% |
| Dec 31, 1999 | 1,108 | 241 | 27.80% |
| Dec 31, 1998 | 867 | 191 | 28.25% |
| Dec 31, 1997 | 676 | 218 | 47.60% |
| Dec 31, 1996 | 458 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| BioNTech SE | 7,807 |
| Moderna | 4,700 |
| Genmab | 2,973 |
| Jazz Pharmaceuticals | 2,890 |
| Insmed | 1,664 |
| Ascendis Pharma | 1,189 |
| Revolution Medicines | 883 |
| BridgeBio Pharma | 839 |
INCY News
- 1 day ago - Incyte Announces FDA Approval of Jakafi XR™ (ruxolitinib) Extended-Release Tablets for the Treatment of Myelofibrosis, Polycythemia Vera and Graft-Versus-Host Disease - Business Wire
- 4 days ago - Incyte to Present at Upcoming Investor Conferences - Business Wire
- 5 days ago - Incyte beats first-quarter estimates on strong demand for cancer drugs - Reuters
- 5 days ago - Incyte Earnings Call Transcript: Q1 2026 - Transcripts
- 5 days ago - Incyte Reports First Quarter 2026 Financial Results and Provides Business Updates - Business Wire
- 5 days ago - Incyte Appoints Suketu (Suky) Upadhyay as Chief Financial Officer - Business Wire
- 12 days ago - Incyte Highlights New Phase 3 Tafasitamab Data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting - Business Wire
- 24 days ago - Incyte to Report First Quarter Financial Results - Business Wire